Page 94 - Read Online

Page 16 of 19 Corn et al. J Cancer Metastasis Treat 2021;7:41 https://dx.doi.org/10.20517/2394-4722.2021.63

malignancy rate and significance of standardised uptake values. Eur J Surg Oncol 2014;40:1528-32. DOI PubMed
34. Karantanis D, Bogsrud TV, Wiseman GA, et al. Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland. J
Nucl Med 2007;48:896-901. DOI PubMed
35. Şencan Eren M, Özdoğan Ö, Gedik A, et al. The incidence of 18F-FDG PET/CT thyroid incidentalomas andthe prevalence of
malignancy: a prospective study. Turk J Med Sci 2016;46:840-7. DOI PubMed
36. Jamsek J, Zagar I, Gaberscek S, Grmek M. Thyroid lesions incidentally detected by (18)F-FDG PET-CT - a two centre retrospective
study. Radiol Oncol 2015;49:121-7. DOI PubMed PMC
37. Salvatori M, Melis L, Castaldi P, et al. Clinical significance of focal and diffuse thyroid diseases identified by (18)F-
fluorodeoxyglucose positron emission tomography. Biomed Pharmacother 2007;61:488-93. DOI PubMed
38. Bae JS, Chae BJ, Park WC, et al. Incidental thyroid lesions detected by FDG-PET/CT: prevalence and risk of thyroid cancer. World J
Surg Oncol 2009;7:63. DOI PubMed PMC
39. Katz SC, Shaha A. PET-associated incidental neoplasms of the thyroid. J Am Coll Surg 2008;207:259-64. DOI PubMed
40. Beck T, Zhang N, Shah A, Khoncarly S, McHenry C, Jin J. Thyroid cancer identified after positron emission tomography (PET)
shows aggressive histopathology. J Surg Res 2021;260:245-50. DOI PubMed
18
41. Kim YH, Chang Y, Kim Y, et al. Diffusely increased F-FDG uptake in the thyroid gland and risk of thyroid dysfunction: a cohort
study. J Clin Med 2019;8:443. DOI PubMed PMC
42. Ozderya A, Temizkan S, Gul AE, Ozugur S, Sargin M, Aydin K. Correlation of BRAF mutation and SUV levels in thyroid cancer
max
18
patients incidentally detected in F-fluorodeoxyglucose positron emission tomography. Endocrine 2017;55:215-22. DOI PubMed
18
43. Makis W, Ciarallo A. Thyroid incidentalomas on F-FDG PET/CT: clinical significance and controversies. Mol Imaging Radionucl
Ther 2017;26:93-100. DOI PubMed PMC
44. Kang BJ, O JH, Baik JH, Jung SL, Park YH, Chung SK. Incidental thyroid uptake on F-18 FDG PET/CT: correlation with
ultrasonography and pathology. Ann Nucl Med 2009;23:729-37. DOI PubMed
45. Chen W, Parsons M, Torigian DA, Zhuang H, Alavi A. Evaluation of thyroid FDG uptake incidentally identified on FDG-PET/CT
imaging. Nucl Med Commun 2009;30:240-4. DOI PubMed
46. Kurata S, Ishibashi M, Hiromatsu Y, et al. Diffuse and diffuse-plus-focal uptake in the thyroid gland identified by using FDG-PET:
prevalence of thyroid cancer and Hashimoto's thyroiditis. Ann Nucl Med 2007;21:325-30. DOI PubMed
47. Nockel P, Millo C, Keutgen X, et al. The rate and clinical significance of incidental thyroid uptake as detected by gallium-68
DOTATATE positron emission tomography/computed tomography. Thyroid 2016;26:831-5. DOI PubMed PMC
48. Pagano L, Samà MT, Morani F, et al. Thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography
with CT (FDG-PET/CT): clinical and pathological relevance. Clin Endocrinol (Oxf) 2011;75:528-34. DOI PubMed
49. Bertagna F, Treglia G, Piccardo A, et al. F18-FDG-PET/CT thyroid incidentalomas: a wide retrospective analysis in three Italian
centres on the significance of focal uptake and SUV value. Endocrine 2013;43:678-85. DOI PubMed
50. Nilsson IL, Arnberg F, Zedenius J, Sundin A. Thyroid incidentaloma detected by fluorodeoxyglucose positron emission
tomography/computed tomography: practical management algorithm. World J Surg 2011;35:2691-7. DOI PubMed
51. Asmar A, Simonsen L, Bülow J, Asmar M. [Work-up of thyroid incidentalomas identified by (18)F-fluorodeoxyglucose PET/CT].
Ugeskr Laeger 2017;179:V12160893. PubMed
52. Yasuda S, Shohtsu A, Ide M, et al. Chronic thyroiditis: diffuse uptake of FDG at PET. Radiology 1998;207:775-8. DOI PubMed
53. Cohen MS, Arslan N, Dehdashti F, et al. Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron
emission tomography. Surgery 2001;130:941-6. DOI PubMed
54. Kim TY, Kim WB, Ryu JS, Gong G, Hong SJ, Shong YK. 18F-fluorodeoxyglucose uptake in thyroid from positron emission
tomogram (PET) for evaluation in cancer patients: high prevalence of malignancy in thyroid PET incidentaloma. Laryngoscope
2005;115:1074-8. DOI PubMed
55. Are C, Hsu JF, Schoder H, Shah JP, Larson SM, Shaha AR. FDG-PET detected thyroid incidentalomas: need for further
investigation? Ann Surg Oncol 2007;14:239-47. DOI PubMed
56. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to
1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002;87:489-99. DOI PubMed
57. Pruthi A, Choudhury PS, Gupta M, Taywade S. Does the intensity of diffuse thyroid gland uptake on F-18 fluorodeoxyglucose
positron emission tomography/computed tomography scan predict the severity of hypothyroidism? Indian J Nucl Med 2015;30:16-20.
DOI PubMed PMC
58. Kim SS, Kim SJ, Bae YT, et al. Factors associated with the development of new onset diffuse thyroid F18-fluorodeoxyglucose uptake
after treatment of breast cancer in patients without a history of thyroid disease or thyroid dysfunction. Thyroid 2012;22:53-8. DOI
PubMed
59. Langer JE, Khan A, Nisenbaum HL, et al. Sonographic appearance of focal thyroiditis. AJR Am J Roentgenol 2001;176:751-4. DOI
PubMed
60. Hwang S, Shin DY, Kim EK, et al. Focal lymphocytic thyroiditis nodules share the features of papillary thyroid cancer on ultrasound.
Yonsei Med J 2015;56:1338-44. DOI PubMed PMC
61. Thuillier P, Crouzeix G, Descourt R, Salaun PY, Abgral R. Progression of focal to diffuse thyroid uptake detected by 18F-FDG
PET/CT: malignant metastatic disease or benign thyroiditis? Clin Nucl Med 2018;43:e310-1. DOI PubMed
62. Poller DN, Megadmi H, Ward MJA, Trimboli P. Hürthle cells on fine-needle aspiration cytology are important for risk assessment of
focally PET/CT FDG avid thyroid nodules. Cancers (Basel) 2020;12:3544. DOI PubMed PMC
63. Noone AM, Howlader N, Krapcho M, et al. SEER cancer statistics review, 1975-2015, National Cancer Institute. Bethesda, MD.